Skip to main content

Table 1 Background of patients

From: Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study

 

Recovered

Died

p valuea

n

%

n

%

Age

  < 60

250

35.8

29

9.3

< 0.001

 60 s

164

23.5

45

14.5

 

 ≥ 70

285

40.8

237

76.2

 

Gender

 Male

497

71.3

212

68.4

0.37

 Female

200

28.7

98

31.6

 

Primary disease

 Chronic glomerulonephritis

123

19.4

37

13.8

0.211

 Diabetes mellitus

328

51.8

147

54.6

 

 Nephrosclerosis

87

13.7

43

16.0

 

 Others

95

15.0

42

15.6

 

Duration of dialysis

 < 1 year

95

13.9

21

7.5

0.015

 1 to < 5 years

257

37.6

94

33.7

 

 5 to < 10 years

164

24.0

78

28.0

 

 10 to < 15 years

83

12.1

45

16.1

 

 ≥ 15 years

85

12.4

41

14.7

 

Complication

 Hypertension

  No

383

56.2

158

57.0

0.83

  Yes

299

43.8

119

43.0

 

 Diabetes mellitus

  No

335

48.4

120

42.7

0.119

  Yes

357

51.6

161

57.3

 

 Cardiovascular disease

  No

420

62.5

131

48.9

< 0.001

  Yes

252

37.5

137

51.1

 

 Chronic respiratory disease

  No

625

92.5

243

89.3

0.122

  Yes

51

7.5

29

10.7

 

 Peripheral arterial disease

  No

585

87.3

198

74.7

< 0.001

  Yes

85

12.7

67

25.3

 

 Malignancy

  No

586

86.8

226

84.0

0.298

  Yes

89

13.2

43

16.0

 

 Number of complications

 0

114

16.5

29

10.2

0.008

 1

218

31.5

80

28.2

 

 ≥ 2

361

52.1

175

61.6

 

Oxygenation

 No

302

44.8

29

10.5

< 0.001

 Yes

320

47.5

174

63.0

 

 Ventilator or ECMO

52

7.7

73

26.4

 

Remdesivir

 No

591

89.0

235

90.0

0.723

 Yes

73

11.0

26

10.0

 

Dexamethasone

 No

374

56.2

107

40.5

< 0.001

 Yes

291

43.8

157

59.5

 
  1. ECMO extracorporeal membrane oxygenation
  2. aFisher’s exact test